Zongertinib after surgery for HER2-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new pill, zongertinib, against standard of care for people with early-stage (II–IIIB) non-small cell lung cancer that has a specific HER2 mutation in the tyrosine kinase domain. The goal is to see if zongertinib can prevent the cancer from coming back after complete surgical removal.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your cancer must be non-small cell lung cancer (NSCLC) with an activating HER2 mutation in the tyrosine kinase domain.
- Your cancer must have been completely removed by surgery, and it cannot have spread beyond stage IIIB before you started treatment.
- You need to be in good general health (ECOG 0 or 1) with adequate organ function.
- You cannot have had major surgery within 4 weeks before the trial starts.
- You cannot have other treatable cancer mutations like EGFR or ALK, or a history of interstitial lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests zipalertinib, a targeted pill for people with non-small cell lung cancer that has an atypical EGFR gene change. It is given after standard treatment like surgery or radiation to help prevent the cancer from coming back.
This trial tests whether taking an EGFR-targeted pill after lung cancer surgery can lower the chance of the cancer coming back. It is for people with early-stage non-small cell lung cancer that has a specific EGFR mutation.
This study tests a combination of two targeted drugs (envafolimab and disitamab vedotin) plus chemotherapy (carboplatin) given before surgery for lung cancer that has a HER2 mutation. The goal is to see if this can shrink the tumor and improve outcomes.
This trial tests a new targeted pill (befotertinib) given before surgery, either with another targeted drug (bevacizumab) or with standard chemotherapy. The goal is to shrink the tumor and improve outcomes for people with a specific type of lung cancer.
This trial tests two medications, trastuzumab rezetecan and adebrelimab, given alone or together, for people with a specific type of stage III lung cancer that has a HER2 change. The goal is to see if these treatments can help control the cancer after standard chemotherapy and radiation.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.